Harmony Biosciences Holdings, Inc.
OX2R
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for OX2R in its lead indication are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“2026 OX2R Phase 1 clinical PK data”